SecBot SecBot
COURT-RULING ·Filed Jul 31, 2026

SNY

Sanofi
BULLISH
Impact 5/10
Horizonimmediate Processed3mo ago CourtCourt Ruling · govinfo.gov
Actionable Insight ▲ Bullish

The affirmance removes a patent overhang on Sanofi's pneumococcal vaccine business. With the IPR final, Sanofi faces no immediate patent challenge from Pfizer on these claims. Monitor for any potential Supreme Court cert petition, though unlikely given the nonprecedential nature. The ruling is a modest positive for SNY's vaccine segment.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$42.95
T+0 close · Aug 3, 2026 · via day close
Latest settled
−2.68%
T+60 · $41.80
Vs SPY
−4.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 3 $42.95entry
  2. T+1 · 4mo ago −0.63%α −2.43% · $42.68
  3. T+5 · 3mo ago +1.23%α −0.79% · $43.48
  4. T+20 · 3mo ago +3.28%α +2.04% · $44.36
  5. T+60 · 21d ago −2.68%α −4.46% · $41.80
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The Federal Circuit affirmed the PTAB's denial of Pfizer's motion to amend patent claims in three IPR proceedings, ruling that Pfizer's proposed substitute claims for pneumococcal vaccine patent U.S. 9,492,559 would have been obvious. This is a final win for Sanofi, removing a potential patent infringement threat to its pneumococcal vaccine franchise.

Court Ruling Details

Ruling Date
Jul 31, 2026
Court
United States Court of Appeals for the Federal Circuit
Court Level
Appellate
Judge
Lourie
Case Type
patent
Ruling Type
final judgment
Outcome
WIN: ruling favors this company
Precedent Risk
LOW

Key Facts

  • Federal Circuit affirmed PTAB's obviousness finding for Pfizer's proposed substitute claims 48 and 49
  • Sanofi (appellee) successfully defended against Pfizer's attempt to amend patent claims covering pneumococcal vaccine compositions
  • Ruling is nonprecedential but final, with no further appeal available
  • Patent U.S. 9,492,559 covers immunogenic compositions with specific S. pneumoniae serotypes conjugated to CRM197

Financial Impact

No damages awarded; ruling eliminates potential patent infringement liability for Sanofi's pneumococcal vaccines, but financial impact is not quantified in the opinion

patent riskvaccine revenue exposure

Risk Factors

  • Pfizer could theoretically seek certiorari, but the nonprecedential disposition and lack of novel legal issues make this unlikely
  • Other patent challenges to Sanofi's pneumococcal vaccine portfolio may still exist

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
55% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 court opinions.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-3479514c72-SNY
COURT-RULING Data (Synthetic)court-6391b880d2-SNY
COURT-RULING Data (Synthetic)court-6a6fb94ccc-SNY

Track record

15 reports on SNY

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +7.69% at T+60 after the Aug 17, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $47.47 to $48.43 Now $48.39 +1.94% ▲ +2.02% +2.94% vs SPY
  2. Oct 30, 202617d ago 6-K Bullish 6/10 Entry $44.34 to $47.04 Now $48.39 +9.13% ▲ +6.09% +8.79% vs SPY
  3. Oct 26, 202621d ago SC 13G/A Neutral 2/10 Entry $41.89 to $45.33 Now $48.39 +15.52% ▲ +8.21% +10.20% vs SPY
  4. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $41.79 to $44.34 Now $48.39 +15.79% ▲ +6.10% +7.36% vs SPY
  5. Oct 1, 20266w ago 6-K Mixed 5/10 Entry $40.67 to $40.23 Now $48.39 +18.98% ▼ −1.08% −2.38% vs SPY
  6. Sep 17, 20268w ago 6-K Neutral 4/10 Entry $43.14 to $40.94 Now $48.39 +12.17% ▼ −5.10% −5.95% vs SPY
  7. Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $44.37 to $42.85 Now $48.39 +9.06% ▼ −3.43% −3.51% vs SPY
  8. Aug 17, 202613w ago Court Ruling Bullish 4/10 Entry $44.97 to $46.02 Now $48.39 +7.61% ▲ +2.33% +2.54% vs SPY
  9. Aug 12, 202613w ago Court Ruling Neutral 2/10 Entry $43.78 to $45.15 Now $48.39 +10.53% ▲ +3.13% +5.09% vs SPY
  10. Jul 31, 202615w ago Court Ruling Bullish 5/10 Viewing Entry $42.95 to $43.48 Now $48.39 +12.67% ▲ +1.23% −0.79% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 9h 19m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Aug 1, 2026